Seeking Alpha


Send Message
View as an RSS Feed
View RandyApsel's Comments BY TICKER:
Latest  |  Highest rated
  • Substantial Value Potential In Recently Underperforming Biotechs [View article]
    Indiansfan407 is right on the money and with the facts. Neither Super Dave nor the author (Brian Wilson) did their homework. It was expected (even by the author) that Synergy would need to raise more operating funds, as do almost all biotechs prior to commercialization. The article totally missed the fact that Synergy floated more shares and raised $84.4M on 16Apr2013, almost four months ago). Take a look at Synergy's Q1 financial report: and you will see that the author ignored the $84.4 public offering discussed in the report and the prto-form balance sheet. Their Q2 financial report should be coming out soon and with a monthly run rate of about $11M, their cash balance should be somewhere around $60M currently, not $21M.

    How could anyone covering a stock not be aware of such an important and well-publicized financial transaction? Either the author was totally negligent or the author purposefully left off the facts to manipulate the stock. In either case, very disturbing, especially since Plecanatide is on target to become a blockbuster drug for treating 2 or 3+ million patients with chronic constipation with far better efficacy than Ironwood's Linzess drug and with none of the significant side effects of Linzess and other drugs.

    The author claims he has no positions (long or short) in SGYP, but with such a significant distortion of the facts, it makes one wonder if the author is long in IRWD and is trying provide the element of doubt in Synergy's ability to compete with Ironwood's far inferior drug.
    Aug 5, 2013. 09:32 PM | Likes Like |Link to Comment
  • Should You Buy Ironwood Pharmaceuticals? [View article]
    Interesting article, however there was no mention of the very real and serious competition from Synergy's Plecanatide drug (stock symbol SGYP), which is in final Phase 3 clinical trial, showing significantly better responses than Linzess and none of the incremental side effects. Once FDA approved, it will make no sense for Linzess to be prescribed over Plecanatide. In fact, that could very well be the reason Linzess sales are underperforming expectations in anticipation of a far superior drug.
    Jul 26, 2013. 05:12 PM | Likes Like |Link to Comment
  • Synergy Pharma (SGYP -3.7%) slips despite presenting positive safety and efficacy results from trials of plecanatide, its drug candidate for patients with chronic idiopathic constipation at an industry conference earlier in Orlando, Florida. The data showed the best improvement in symptoms were observed in patients receiving 3-milligram doses of plecanatide. [View news story]
    I agree. The upside potential is huge for Plecanetide and the downside risks appear to be behind us: (1) their $90M financing for the next 12 months operations is already in the bank from the grossly oversold share dilution below the discounted $5.50 price for the institutional investors; (2) the safety and efficacy clinical trials are complete with just one additional 3x dosage trial underway to broaden the NDA further prior to FDA approval; and (3) the big pharma companies are always on the lookout for the next blockbuster drug and Synergy will most likely be a prime M&A candidate at a significant premium from current prices. So, definitely thanks to those investors doing the typical "selling on the good news", because this is another STRONG BUYing opportunity especially at the current oversold levels. Full disclosure -- I just bought more shares.
    May 21, 2013. 04:15 PM | Likes Like |Link to Comment